Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/TheBodyPRO.com cover the XVIII International AIDS Conference (AIDS 2010)
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Update: 2010 International AIDS Conference

Tales From Vienna: The World's AIDS Community Converges Upon Vienna for the International AIDS Conference

September/October 2010

 1  |  2  |  Next > 

Conference attendees gather at the Human Rights Rally and March held at Heldenplatz in Vienna.

Conference attendees gather at the Human Rights Rally and March held at Heldenplatz in Vienna.

More than 16,000 delegates traveled to Vienna, Austria for the 18th International AIDS Conference held in July. Abstracts (summaries) and many webcasts are available at www.aids2010.org.

Leading the news from the conference: the first ever antiviral-based gel to show effectiveness in preventing HIV in women.


A New Weapon Women Can Use Against the Virus

Doctors don't usually get a standing ovation when presenting data from a study, but Dr. Quarraisha Abdool Karim did.

She presented study results showing a 39% decrease in HIV infections in women using a vaginal gel containing tenofovir, an anti-HIV medication. The gel was used up to 12 hours before sex and again afterwards.

Moreover, in women who used the microbicide (germ-killing) gel in 80% of the incidences of sexual intercourse, there was a 51% reduction in infection. These women made up the majority of the participants using the gel.

A smaller group of women using the gel less than half the time had a lower success rate, a 28% reduction in infection, but this is still one in four women remaining uninfected.

In addition, the gel prevented herpes infection in 54% of women.

After years of disappointing results with microbicide research, advocates around the world expressed elation. "Goooooal!" wrote Science reporter Jon Cohen.

Nearly 900 women participated in the study at the Centre for the AIDS Programme of Research in South Africa (CAPRISA), with the major funder being USAID (U.S. Agency for International Development).

The U.S. and South African governments were the primary forces behind the study. Dr. Abdool Karim is with Columbia University and associate director of CAPRISA, where her husband, Dr. Salim S. Abdool Karim is director. He is also a vice-chancellor at the University of KwaZulu-Natal (UKZN) in South Africa.

In a UKZN press release, Dr. Quarraisha Abdool Karim says that, "Tenofovir gel could fill an important HIV prevention gap by empowering women who are unable to successfully negotiate mutual faithfulness or condom use with their male partners. This new technology has the potential to alter the course of the HIV epidemic, especially in southern Africa where young women bear the brunt of this devastating disease."

A YouTube video of interviews with some of the women and medical providers in the study, entitled "Gabi's Gift," is available, along with other information on the results, at www.caprisa.org. In it, Gabi Nxele explains that a friend died of AIDS and participating in the study was her gift to the women of the world.

Anthony Fauci at the CAPRISA press conference. Former president Bill Clinton. Columbia University's Quarraisha Abdool Karim.

Anthony Fauci at the CAPRISA press conference. Former president Bill Clinton. Columbia University's Quarraisha Abdool Karim.

A mathematical model presented at the conference estimated that "a vaginal microbicide with an efficacy of 40% to 50% could prevent between 271,000 and 602,000 new HIV infections in 10 years [in South African women] depending on coverage." This depends on the gel's effectiveness being confirmed in further research. For example, a tenofovir gel combined with pills is being studied by the Microbicide Trials Network (MTN). The model also depends on the gel becoming available within five years.

In the CAPRISA study, usage fell off over time. There was a 50% prevention rate in the first year, which went down to 39% for the entire two and a half years of the study. The success rate was compared against women who were given a placebo gel (no active substance).

Tenofovir is available as an HIV drug called Viread, and is in the HIV medications Truvada and Atripla, both best-selling compounds. It is also being studied as a prevention pill for HIV-negative people at high risk of infection. There's long been hope and excitement for tenofovir, and Truvada, to help in the prevention of HIV during sexual encounters. Newer HIV drugs are also being studied for this purpose.

Two U.S.-based organizations, FHI (Family Health International) and CONRAD (Contraceptive Research and Development Program), collaborated with CAPRISA. MTN reported that Gilead Sciences, which makes tenofovir, initially created the gel and granted a royalty-free license for it to CONRAD and to the International Partnership for Microbicides. Gilead provided tenofovir for free to MTN.

CONRAD is a division of the Department of Obstetrics and Gynecology at Eastern Virginia Medical School, with a mission to help rapidly develop safe, affordable, and effective products for contraception and prevention of sexually transmitted HIV and other infections.

CONRAD offered to lead the movement to have the gel released as soon as possible if it continues to show effectiveness. Advocates noted that government regulations around the world prevent the availability of products for years after they are found to be effective.

The study publication is available free online at www.sciencemag.com.


The Vienna Declaration

It's time to stop the harmful laws and discrimination associated with the international war against drugs, according to doctors, researchers, and advocates who created the Vienna Declaration. The statement urges the promotion of syringe exchange and other proven methods of protecting health.

Advertisement

"The criminalization of illicit drug users is fuelling the HIV epidemic and has resulted in overwhelmingly negative health and social consequences," they wrote. "A full policy reorientation is needed."

The declaration goes on to briefly review the history of this war on drugs and discuss its failings.

Among the problems discussed is a high rate of HIV among injection drug users (IDUs) in areas of the world where the virus is "spreading rapidly." In Eastern Europe and Central Asia, as many as 70% of IDUs become infected, and in some areas, more than 80% of this group acquires HIV.

"In the context of overwhelming evidence that drug law enforcement has failed to achieve its stated objectives, it is important that its harmful consequences be acknowledged and addressed," the declaration continues.

The following points, taken directly from the declaration, represent some of the consequences of the war on drugs:

  • A crisis in criminal justice systems as a result of record incarceration rates in a number of nations. This has negatively affected the social functioning of entire communities. While racial disparities in incarceration rates for drug offences are evident in countries all over the world, the impact has been particularly severe in the U.S., where approximately one in nine African American males between the ages of 20 to 34 is incarcerated on any given day, primarily as a result of drug law enforcement.
  • Stigma towards people who use illicit drugs, which reinforces the political popularity of criminalizing drug users and undermines HIV prevention and other health promotion efforts.
  • Severe human rights violations, including torture, forced labor, inhumane and degrading treatment, and execution of drug offenders in a number of countries.

Brigitte Schmied was among the presenters at the opening press conference. Bill Gates discusses HIV prevention strategies.

Brigitte Schmied was among the presenters at the opening press conference. Bill Gates discusses HIV prevention strategies.

"Unfortunately, evidence of the failure of drug prohibition to achieve its stated goals, as well as the severe negative consequences of these policies, is often denied by those with vested interests in maintaining the status quo," the declaration says. "This has created confusion among the public and has cost countless lives. Governments and international organizations have ethical and legal obligations to respond to this crisis and must seek to enact alternative evidence-based strategies that can effectively reduce the harms of drugs without creating harms of their own." The document goes on to make several recommendations.

The declaration also notes that, "Basing drug policies on scientific evidence will not eliminate drug use or the problems stemming from drug injecting. However, reorienting drug policies towards evidence-based approaches that respect, protect, and fulfill human rights has the potential to reduce harms deriving from current policies and would allow for the redirection of the vast financial resources towards where they are needed most: implementing and evaluating evidence-based prevention, regulatory, treatment and harm reduction interventions."

Individuals and organizations are invited to sign the Vienna Declaration at www.viennadeclaration.com.

 1  |  2  |  Next > 


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
 
See Also
More on HIV Treatment Research
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

AIDS 2010
Home
Choose a Topic:
Previous Conferences

Advertisement